CN107828705A - One bacillus amyloliquefaciens and its application in preventing and treating autism - Google Patents
One bacillus amyloliquefaciens and its application in preventing and treating autism Download PDFInfo
- Publication number
- CN107828705A CN107828705A CN201711496671.1A CN201711496671A CN107828705A CN 107828705 A CN107828705 A CN 107828705A CN 201711496671 A CN201711496671 A CN 201711496671A CN 107828705 A CN107828705 A CN 107828705A
- Authority
- CN
- China
- Prior art keywords
- bacillus amyloliquefaciens
- autism
- bacillus
- group
- rat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010003805 Autism Diseases 0.000 title claims abstract description 37
- 208000020706 Autistic disease Diseases 0.000 title claims abstract description 37
- 241000193744 Bacillus amyloliquefaciens Species 0.000 title claims description 60
- 244000005700 microbiome Species 0.000 claims abstract description 11
- 238000004321 preservation Methods 0.000 claims abstract description 8
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
- 241000894006 Bacteria Species 0.000 description 31
- 241000700159 Rattus Species 0.000 description 30
- 201000010099 disease Diseases 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 239000007788 liquid Substances 0.000 description 14
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 13
- 229910052753 mercury Inorganic materials 0.000 description 13
- 238000012549 training Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 241000193749 Bacillus coagulans Species 0.000 description 10
- 229940054340 bacillus coagulans Drugs 0.000 description 10
- 230000006399 behavior Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000011273 social behavior Effects 0.000 description 10
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 241000062285 Bacillus amyloliquefaciens group Species 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000002068 microbial inoculum Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000011552 rat model Methods 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 230000009514 concussion Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000003997 social interaction Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000252983 Caecum Species 0.000 description 4
- 241000726221 Gemma Species 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000035478 Interatrial communication Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000013914 atrial heart septal defect Diseases 0.000 description 3
- 206010003664 atrial septal defect Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008131 children development Effects 0.000 description 3
- 230000003930 cognitive ability Effects 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- JJWSNOOGIUMOEE-UHFFFAOYSA-N Monomethylmercury Chemical compound [Hg]C JJWSNOOGIUMOEE-UHFFFAOYSA-N 0.000 description 2
- 101710089165 Protein white Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000006854 communication Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical compound [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000021317 sensory perception Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000012859 sterile filling Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010082340 Arginine deiminase Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000002161 echolalia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a bacillus amyloliquefaciensBacillus amyloliquefaciensYHSH‑58And its application in preventing and treating autism, for the strain in the preservation of Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3 China Committee for Culture Collection of Microorganisms's common micro-organisms center, deposit number is that CGMCC NO.13664 preservation dates are on 2 16th, 2017.
Description
Technical field
The present invention relates to microorganism medicine prevention or treatment autism preparation are being prepared with protecting a bacillus amyloliquefaciens
In application, specifically with bacillus amyloliquefaciens YHSH-58 prevent or treat autism, reduce autistic symptoms.
Background technology
What is unsociable and eccentric disease！Unsociable and eccentric disease is a kind of brain disorders symptom of generally existing.Pay attention to：It is a kind of imbalance, and
It is not a kind of disease.
How universal this imbalance have on earth, and assessment of the people to unsociable and eccentric disease illness rate is had nothing in common with each other, and this depends on dry clinic
Standard.Some assessments show that the illness rate of unsociable and eccentric disease is very low, there was only 5 in every 10000 people；But also there are some assessments to show to suffer from
Sick rate is very high, just has 1 in every 80 people.
Unsociable and eccentric disease patient --- there are three kinds of classical symptoms：Poor Social Interaction, oral and non-verbal communication disorder,
Unusual or critical constraints behaviors and interest.More specifically say, the people with unsociable and eccentric disease may more be keen to thinking for oneself
Method, it is impossible to carry out social activities；They may also have behavioral problem and aphasis (such as echo-speech).In addition, with orphan
The people of out-of-the-way disease usually can make abnormal reaction to sound, perception and other stimulus to the sense organ.
In the first three years for childhood that unsociable and eccentric disease typically occurs in, and can be in the continuity in life of people.In many child patients
In one, these symptoms can be improved with the interference or the growth at age in the external world.Some unsociable and eccentric disease patients --- eventually exist
Run one's life in normal and almost normal state.
Sometimes, numerous unsociable and eccentric disease symptoms can be classified as general self-closing disease disorders syndrome or atrial septal defect.
This classification meets such theory：Unsociable and eccentric disease patient one would generally several diseases it is concurrent.The about 1/3 general self-closing disease that suffers from hinders
The children of syndrome are hindered eventually to suffer from insane carbuncle disease.There is the people of serious cognitive question and broken hair stroke symptom to suffer from this sick
Risk is highest.
Currently there are no medicine can cure unsociable and eccentric disease completely, the various prescriptions that doctor outputs, can only play mitigation.
But, without worrying, the people with unsociable and eccentric disease was still hopeful normal life, and probiotics brings new wish for them
Hope.Cui Yunlong etc. discloses clostridium butyricum in the patent No. 2016110603254 can have certain treatment autism with reducing
The function of autistic symptoms, there is the report of preventing and treating autism but without report bacillus amyloliquefaciens.
The content of the invention
It is an object of the invention to provide a bacillus amyloliquefaciens Bacillus amyloliquefaciensYHSH-58
And its application in preventing and treating autism, the strain is in Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3 Chinese microorganism strain
The common micro-organisms center preservation of preservation administration committee, deposit number are that CGMCC NO.13664 preservation dates are 2 months 2017
16 days；
Wherein, the preparation of bacillus amyloliquefaciens preparation can be prepared according to the following steps（It can also be prepared with other methods）：
First, culture presevation pipe is taken out, flat board is drawn with LB solid mediums and is recovered, 37 DEG C are cultivated 48 hours.Chosen under flat board
Single bacterium colony is taken to be inoculated with 50 milliliters of LB culture mediums, 37 DEG C of concussion and cultivates 24 hours in incubator.Seed uses 5% inoculation
Amount, it is seeded in the big triangular flasks of 5L that liquid amount is 2LLB culture mediums, 33 DEG C of concussion and cultivate 20-28 hours, it is dense detects its bacterium solution
Degree, viable bacteria content is more than 2,000,000,000/milliliter, you can as bacillus amyloliquefaciens liquid spawn；
2nd, using the bacillus amyloliquefaciens liquid spawn of step 1 culture as seed, 600L fermentation mediums is seeded to, are inoculated with
Measure as 10%, open stirring 120r/min, minute ventilation volume liquid-gas ratio 1：0.8,33 DEG C of culture 24-36 hour, treat spore content not
Less than 10,000,000,000 CFU/ml, you can terminate fermentation, sterile filling obtains finished product bacillus amyloliquefaciens microbial inoculum；Or obtain zymotic fluid
It is spray-dried afterwards plus dextrin, obtains bacillus amyloliquefaciens pulvis, its pulvis spore content is not less than 10,000,000,000 CFU/g；
Wherein, the LB culture mediums：Peptone 5g, beef extract 3g, sodium chloride 5g, water 1000mL, pH7.2, in solid medium
Add agar 2%；
Wherein, the fermentation medium：Soybean separation protein white powder 40 g/L, glucose 10g/L, the g/L of soluble starch 10, egg
White peptone 5 g/L, the g/L of magnesium sulfate 0.3, the g/L of manganese sulfate 0.05, potassium dihydrogen phosphate 0.5 g/L, pH7.2；Each medium sterilization
Condition is：0.10-0.15MPa, 121 DEG C sterilize 30 minutes；
Bacillus amyloliquefaciens of the present inventionYHSH-58Medicine, health food, food or drink etc. can be made.
The signified effective dose of the present invention refers to bacillus amyloliquefaciens YHSH-58 as made of key agents active ingredient
Total viable count that solid live bacteria preparation includes cannot be below 1 × 109CFU/g,
The signified effective dose of the present invention refers to bacillus amyloliquefaciens YHSH-58 as liquid made of key agents active ingredient
Total viable count that active bacteria formulation includes cannot be below 5 × 108CFU/mL.
The bacillus amyloliquefaciens preparation of the present invention can effectively prevent or treat autism, hence it is evident that reduce lonely symptom, and nothing
Any poison
Side effect, it is good using compliance, it is prevention or treats the new method of autism, new breakthrough.The solution starch gemma of the present invention
Bacillus can effectively prevent and treat autism and may be played a role in terms of following three：
First, bacillus amyloliquefaciens YHSH-58 of the invention can repair intestines leakage, set physical obstacle, prevent harmful bacteria
Caused bacteremia (or bacterium is produced in blood) in (or pathogen) intrusive body.Bacillus amyloliquefaciens can not only be from physiology
Upper blocking harmful bacterium, moreover it is possible to alleviate these bacterial pain, make body get well gradually.This largely promotees
Body ego treatment is entered.
Second, in unsociable and eccentric disease PATIENT POPULATION, it is a kind of popular way to carry out comprehensive toxin expelling to body.Doctor
Conventional toxin expelling material includes DMSA, this kind of materials of EDTA and mixture (chelating means to catch or surrounds some things) etc..Row
Poison has relation with treating unsociable and eccentric disease because the mercury obtained from environment one by one the life from surrounding or soil make to absorb in environment or
That absorbed by vaccine inoculation is the arch-criminal that causes unsociable and eccentric disease and atrial septal defect one by one.
General principle is such, and gut associated lymphoid tissue (GALT) plays in the foundation and evolution of unsociable and eccentric disease
Key-like role.The bacillus amyloliquefaciens of the present invention may promote the growth of some enteric bacteria or itself can pass through
Toxin expelling is carried out using mole factor pair methyl mercury is (organic).Mole factor is exactly by the way that organomercurial compound is changed into volatilization
Property or the less native mercury of toxicity and inorganic mercury exclude their toxicity.
Mole factor is organized in mole factor set of a regular manipulation, it can be collected in chromosome or
Outside chromosome.Mole factor set includes：For adjusting mole R of protein coding；Protein coding is reduced for water anion
Mole A；One or more gene mole P, mole T and/or mole C.They are all for for mercury ion to be moved into cytoplasm
In protein coding.People are being continuously increased to the interest of the bacterium of these storage genes, because they be able to may be arranged
Except the toxicity of internal mercury.
It is obvious that when the bacillus amyloliquefaciens of the present invention promote enteric microorganism bacterium or itself start to absorb mercury
When, a greater amount of new enteric microorganism bacterium will be needed in vivo to replace performing the probiotics of this task.Purpose is not configured to
Promote persistent loop, but the mercury in enteric microorganism bacterium and other wastes are excreted together, and the Xie Dian in the present invention
Enteric microorganism bacterium is considerably increased after the use of afnyloliquefaciens, and preferably excretes mercury and other wastes.
3rd, the toxicant (ammonia) in unsociable and eccentric disease blood samples of patients is another research field.Use the solution of the present invention
Bacillus amyloliquefacienses are easy for that the ammonia in circulation can be reduced.We have found that 10,000,000,000 of (or in excrement) in caecum thing are contained
The organism for having bacillus amyloliquefaciens is tested, and as a result finds that the pH value of caecum thing correspondingly have dropped（Solve starch bud
Spore bacillus enters quick consumption oxygen after enteron aisle, the growth of intestinal lactobacillus or Bifidobacterium is promoted, so as to reduce intestines
Road pH）.This using bacillus amyloliquefaciens just to provide foundation in the works in toxin expelling.
Embodiment
The separation of the bacillus amyloliquefaciens of embodiment 1
In December, 2014, bacillus amyloliquefaciens (Bacillus amyloliquefaciens) bacterial strain is in Hunan Province Longhui County
It is isolated in the intestinal contents of the wild wild boar in beachhead town field.Specific method is：Take the enteron aisle content of wild wild boar
Thing is added in the triangular flask for filling 10mL aqua sterilisas, concussion and cultivate 30min (200r/min), then takes suspension 1mL to be placed in
In 9mL sterilized waters, 10 are made-2Diluted suspension liquid, the like, it is made 10-5, 10-6Dilute suspension；It is each wherein to draw 100
U L, it is added on nutrient broth medium flat board, uniform with coating rod coating, each processing is repeated 3 times.By above-mentioned culture dish, put
1-2d is cultivated in 37 DEG C of constant incubators.Picking individual colonies are transferred to nutrient broth flat board culture, after growing bacterium colony, with inoculation
Ring carries out line and isolated and purified, and purifying bacterial strain is in 4 DEG C of preservations.
Monoclonal grows the bacterium colony to be formed to the bacterial strain that separation, purifying obtain on nutrient broth medium is circular,
Surrounding is smooth, milky；Cell shape is shaft-like, and cell dia is more than lum；Gemma is formed, does not form parasporal crystal；Aerobe
It is long；Catalase, oxydase reaction are the positive；Arginine dihydrolase, lysine take off shuttle enzyme, ornithine takes off shuttle enzyme, arteries and veins enzyme, color ammonia
The de- shuttle enzyme reaction of acid is feminine gender；VP is tested and nitrate reduction is the positive；Glucose, xylose, L-arabinose, sweet dew can be utilized
Sugar, lactose, sucrose, sorbose, semen armeniacae amarae former times；Melibiose, rhamnose, inositol etc. can not be utilized.Optimal pH is 6-8.5, most suitable
Growth temperature is 25-38 DEG C, and bacillus amyloliquefaciens are accredited as by 16s rDNA.
The preparation of the bacillus amyloliquefaciens preparation of embodiment 2
First, culture presevation pipe is taken out, flat board is drawn with LB solid mediums and is recovered, 37 DEG C are cultivated 48 hours.Chosen under flat board
Single bacterium colony is taken to be inoculated with 50 milliliters of LB culture mediums, 37 DEG C of concussion and cultivates 24 hours in incubator.Seed uses 5% inoculation
Amount, it is seeded in the big triangular flasks of 5L that liquid amount is 2LLB culture mediums, 33 DEG C of concussion and cultivate 20-28 hours, it is dense detects its bacterium solution
Degree, viable bacteria content is more than 2,000,000,000/milliliter, you can as bacillus amyloliquefaciens liquid spawn；
2nd, using the bacillus amyloliquefaciens liquid spawn of step 1 culture as seed, 600L fermentation mediums is seeded to, are inoculated with
Measure as 10%, open stirring 120r/min, minute ventilation volume liquid-gas ratio 1：0.8,33 DEG C of culture 24-36 hour, treat spore content not
Less than 10,000,000,000 CFU/ml, you can terminate fermentation, sterile filling obtains finished product bacillus amyloliquefaciens microbial inoculum；Or obtain zymotic fluid
It is spray-dried afterwards plus dextrin, obtains bacillus amyloliquefaciens pulvis, its pulvis spore content is not less than 10,000,000,000 CFU/g；
Wherein described LB culture mediums：Peptone 5g, beef extract 3g, sodium chloride 5g, water 1000mL, pH7.2, in solid medium plus
Enter agar 2%；
Wherein described fermentation medium：Soybean separation protein white powder 40 g/L, glucose 10g/L, the g/L of soluble starch 10, egg
White peptone 5 g/L, the g/L of magnesium sulfate 0.3, the g/L of manganese sulfate 0.05, potassium dihydrogen phosphate 0.5 g/L, pH7.2；Each medium sterilization
Condition is：0.10-0.15MPa, 121 DEG C sterilize 30 minutes.
The safety testing of the bacillus amyloliquefaciens of embodiment 3
The bacillus amyloliquefaciens liquid that the embodiment of the present invention 2 produces is in Shaoyang institute through rat acute toxicity test, conclusion The results
Show bacillus amyloliquefaciens liquid to rat（Bacillus amyloliquefaciens liquid of the present invention is fed by 0.6ml/10g body weight 14 days）Effect
Fruit：Rat all survive, activity freely, hair smoothing, diet is normal, respiratory tract, eye and oral cavity etc. without secretion outside, do not send out
What incumbent poisoning symptom, body weight have increase.With blank group control group, compare, feed the rat of this bacillus amyloliquefaciens liquid
Body weight substantially increases（P ＜ 0.001）.14 day observation period terminated, by rat dislocate put to death dissection, visually observe the heart, liver, spleen, lung,
The internal organs such as kidney, brain, intestines, small intestine are showed no obvious abnormalities performance.In addition, rat chest gland coefficient and Spleen coefficient result show, with
Blank control group compares, and bacillus amyloliquefaciens liquid rats in test groups Spleen coefficient substantially increases（P ＜ 0.01）, prompt this Xie Dian
Afnyloliquefaciens liquid has an immunological enhancement, true border non-toxic type material, and degree of safety is big.
Animal experiment of the bacillus amyloliquefaciens of embodiment 4 in autism is treated
It is prepared by 1 model group：
1.1 experimental animals select adult Wistar rats：Adult SPF level Wistar female rats 40, male rat 40.
The filial generation male rat (35d, weight 80-100g after birth) 80 that mouse female, great and mighty or powerful gives birth to after mating.
1.2 preparation methods mate mouse female, great and mighty or powerful overnight, the next morning is to female mice with reference to Schneider etc. method
Vaginal smear examination is carried out, it is found that cloudy bolt person is designated as gestation the 1st day, and pregnant dams are individually raised.Pregnant dams press model group：It is right
According to group=4：1 quantity is grouped at random, and at the 12.5th day, the pregnant mouse of model group was disposable by 600mg/kg dosage abdominal cavity
Inject sodium vedproate (VPA), the physiological saline of the pregnant mouse intraperitoneal injection equivalent of control group.The young mouse that the pregnant mouse of model group gives birth to is orphan
Only disease model group, and the young mouse that the pregnant mouse of control group gives birth to is control group.Pl is designated as after young mouse birth within the 1st day.Establish rat orphan
Only disease model.
1.3 model groups prepare result modeling success.
2 drug therapies are tested：
2.1 experimental methods randomly select 35 ages in days (P35) autism newborn mouse 60, control group newborn mouse 20.Wherein control group is young
Mouse is that autism group newborn mouse ((n=20), is randomly divided into bacillus amyloliquefaciens group, bacillus coagulans by Normal group（East
Extra large medicine company production）, model control group 3 groups ((n=20).Each treatment group and control group give identical basal feed, and raise
Condition is consistent, and it is 1 × 10 that bacillus coagulans group is used containing bacterium number with bacillus amyloliquefaciens group60.9% lifes of CFU/mL
Reason salt solution modulation bacterium powder) bacterium solution gavage 0.5mL, model control group and control group group gavage 0.9% physiological saline 0.5mL daily,
Continuous 2 weeks.Influence of the bacillus amyloliquefaciens to autism rat behavior is observed, and is compared with bacillus coagulans group
Compared with.
2.2 Behavior evaluations carry out Behavior evaluation to experimental mouse, including social interaction behavioral value (hide by social action
Phase, duration, number), repeat behavioral value (reason hair cumulative time) and learning and memory tests (test of Moirrs water mazes).
Choose, weight difference identical with detection mouse date of birth and be less than the male mouse of 15g, sub-cage rearing as the auxiliary progress of strange mouse
Social interaction behavioral value.Data carry out statistical analysis using SPSS 21.0.
3 results
3.1 social interaction behavior evaluations
Compared with control group, autism rat model Social behaviors number reduces ((P<0.01), social incubation period increase (P<
0.01), the Social behaviors duration reduces (P<0.01), difference is statistically significant.The Xie Dian compared with autism rat model
After the treatment of afnyloliquefaciens group, rat Social behaviors number increase (P<0.05), there is duration increase ((P in Social behaviors<
0.05), social incubation period reduces ((P<0.05), difference has statistical significance.With bacillus coagulans treatment group rat phase
Than bacillus amyloliquefaciens group rat Social behaviors number increase (P<0.05), social action incubation period reduces ((P<0.05),
The social action duration increases ((P<0.05), difference has statistical significance.Between bacillus amyloliquefaciens group, rat society
Bank of Communications is number, duration, social incubation period no difference of science of statistics ((P occur in Social behaviors>0.05).Solve starch gemma bar
Bacterium is significantly higher than bacillus coagulans treatment group to the effect of being significantly improved of the Social behaviors of autism rat.It the results are shown in Table
1。
The bacillus amyloliquefaciens of table 1 are to the effect of being significantly improved of the Social behaviors of autism rat
3.2 repeat behavior evaluation
Compared with control group, autism rat model reason hair accumulated time increase ((P<0.01), difference is statistically significant；
Compared with autism rat model, after bacillus amyloliquefaciens treatment, rat reason hair accumulated time shortens ((P<0.05), difference
It is statistically significant；Compared with bacillus coagulans group rat, bacillus amyloliquefaciens group rat reason hair accumulated time shortens
((P<0.05), difference is statistically significant；Bacillus amyloliquefaciens can substantially reduce the repetition behavior of autism rat, and it is imitated
Fruit is significantly higher than bacillus coagulans.It the results are shown in Table 2.
The different group rats of table 2 repeat Behavioral change statistical analysis
3.3 ability of learning and memory are assessed
Compared with control group, the poor ((P of autism rat model ability of learning and memory<0.01), difference is statistically significant；With
Autism rat model is compared, and after bacillus amyloliquefaciens treatment, learning and memory in rats ability improves ((P<0.05), difference has
Statistical significance；Compared with bacillus coagulans group rat, bacillus amyloliquefaciens group learning and memory in rats ability improves ((P<
0.05), difference is statistically significant.Bacillus amyloliquefaciens can significantly improve the ability of learning and memory of autism rat, and it is imitated
Fruit is significantly higher than bacillus coagulans.It is shown in Table 3.
The different group learning and memory in rats ability statistical analyses of table 3 you s
4 conclusions
The Social behaviors that autism model group compares rat with Normal group substantially reduce, and the behavior of repetition dramatically increases,
Ability of learning and memory is poor, and after bacillus amyloliquefaciens are treated, Social behaviors number increase ((P<0.05) it is, social latent
The volt phase drops
Low ((P<0.05), grooming accumulated time reduces ((P<0.05), ability of learning and memory improves ((P<0.05), and treat
Effect is aobvious
Work is better than bacillus coagulans treatment group.Show that bacillus amyloliquefaciens intervention can substantially reduce the lonely of autism rat
Disease symptom.Bacillus amyloliquefaciens preparation can effectively prevent or treat autism, hence it is evident that lonely symptom is reduced, and without any poison
Side effect, it is good using compliance, it is prevention or treats the new method of autism, new breakthrough.The solution starch gemma of the present invention
Bacillus can effectively prevent and treat autism and may be played a role in terms of following three：
First, bacillus amyloliquefaciens YHSH-58 of the invention can repair intestines leakage, set physical obstacle, prevent harmful bacteria
Caused bacteremia (or bacterium is produced in blood) in (or pathogen) intrusive body.Bacillus amyloliquefaciens can not only be from physiology
Upper blocking harmful bacterium, moreover it is possible to alleviate these bacterial pain, make body get well gradually.This largely promotees
Body ego treatment is entered.
Second, in unsociable and eccentric disease PATIENT POPULATION, it is a kind of popular way to carry out comprehensive toxin expelling to body.Doctor
Conventional toxin expelling material includes DMSA, this kind of materials of EDTA and mixture (conjunction of stinging means to catch or surrounds some things) etc..Row
Poison has relation with treating unsociable and eccentric disease because the mercury obtained from environment one by one the life from surrounding or soil make to absorb in environment or
That absorbed by vaccine inoculation is the arch-criminal that causes unsociable and eccentric disease and atrial septal defect one by one.
General principle is such, and gut associated lymphoid tissue (GALT) plays in the foundation and evolution of unsociable and eccentric disease
Key-like role.The bacillus amyloliquefaciens of the present invention may promote the growth of some enteric bacteria or itself can pass through
Toxin expelling is carried out using mole factor pair methyl mercury is (organic).Mole factor is exactly by the way that organomercurial compound is changed into volatilization
Property or the less native mercury of toxicity and inorganic mercury exclude their toxicity.
Mole factor is organized in mole factor set of a regular manipulation, it can be collected in chromosome or
Outside chromosome.Mole factor set includes：For adjusting mole R of protein coding；Protein coding is reduced for water anion
Mole A；One or more gene mole P, mole T and/or mole C.They are all for for mercury ion to be moved into cytoplasm
In protein coding.People are being continuously increased to the interest of the bacterium of these storage genes, because they be able to may be arranged
Except the toxicity of internal mercury.
It is obvious that when the bacillus amyloliquefaciens of the present invention promote enteric microorganism bacterium or itself start to absorb mercury
When, a greater amount of new enteric microorganism bacterium will be needed in vivo to replace performing the probiotics of this task.Purpose is not configured to
Promote persistent loop, but the mercury in enteric microorganism bacterium and other wastes are excreted together.
3rd, the toxicant (ammonia) in unsociable and eccentric disease blood samples of patients is another research field.Use the solution of the present invention
Bacillus amyloliquefacienses are easy for that the ammonia in circulation can be reduced.We have found that 10,000,000,000 of (or in excrement) in caecum thing are contained
The organism for having bacillus amyloliquefaciens is tested, and as a result finds that the pH value of caecum thing correspondingly have dropped（Solve starch bud
Spore bacillus enters quick consumption oxygen after enteron aisle, the growth of intestinal lactobacillus or Bifidobacterium is promoted, so as to reduce intestines
Road pH）.This using bacillus amyloliquefaciens just to provide foundation in the works in toxin expelling.
The bacillus amyloliquefaciens of embodiment 5 are tested in autism children therapy
To 0-6 year autism children of selected 120 Association for the Handicapped of Foshan City registration, training, its basic condition such as table 4, use
Speech training, Behavioral training, sense system synthesis, music treatment and probiotic therapy carry out comprehensive rehabilitation training.Instructed with rehabilitation
It is observing time window to practice 6 months and 12 months, after counting each infant respectively by training《Autism child development evaluation quantity
Table》In eight fields：Sensory perception, gross motor, fine movement, language communication, cognitive ability, social interaction, energy of taking care of oneself
Power and mood and the test and appraisal score of behavior, as the autism child development of table 5 assesses table assignment.According to test and appraisal total score, use
The method of Self-controlled study, assess the effect of rehabilitation training.
Test group：Carry out drinking microbial inoculum while the routine recovery training, drink 150 milliliters of microbial inoculum for each person every day, in the morning, afternoon and evening three times
Drink
Control group：Carry out the routine recovery training.
The autistic patients basic condition of table 4
The autism child development of table 5 assesses table assignment
Table 6 drinks the test group and control group rehabilitation concrete condition of bacillus amyloliquefaciens
Test group：Carry out drinking microbial inoculum while rehabilitation training, drink 150 milliliters of microbial inoculum for each person every day, drink three times in the morning, afternoon and evening
Control group：Carry out rehabilitation training
Result of the test：Come as can be seen from Table 6, after the routine recovery training of 6 months, infant in mood and behavior and
Raising is more significant before two field scores of cognitive ability are relatively trained, more than 70%；And take care of oneself, gross motor field score
Improve relatively slow, below 30%, other each field score increase rates are 30%^'50%.By the rehabilitation training of 12 months
Afterwards, raising more than 200% before infant cognitive ability and the score in sensory perception field are relatively trained, and self care ability and thick
It is relatively low to act score raising degree, still, also all improves close to 100%.
But it is relative with drinking for the test group of bacillus amyloliquefaciens, no matter rehabilitation 6 months or 12 months, its
Effect is all significantly higher than the effect of the routine recovery training, sees from total score on it, rehabilitation 6 months, test group total score ratio
Control group improves 40%, and rehabilitation 12 months, test group total score improves 22% than control group, you can it is obvious shorten rehabilitation duration with
Improve rehabilitation efficiency.Facts have proved the bacillus amyloliquefaciens of the present invention has obvious effect to treatment autism.
Claims (4)
- A 1. bacillus amyloliquefaciensBacillus amyloliquefaciensYHSH-58And its in preventing and treating autism Using the strain is commonly micro- in Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3 China Committee for Culture Collection of Microorganisms Bio-Centers preservation, deposit number are CGMCC NO.13664, and preservation date is on 2 16th, 2017.
- 2. applied as described in claim 1, it is characterised in that the preparation prepared including bacillus amyloliquefaciens YHSH-58 is independent Using or with other drugs use in conjunction.
- 3. applied as described in claim 1, it is characterised in that the preparation includes medicine, health food, food, drink.
- 4. applied as described in claim 1, it is characterised in that the preparation meaning effective dose refers to bacillus amyloliquefaciens The total viable counts of YHSH-58 cannot be below 5 × 108CFU/g。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711496671.1A CN107828705A (en) | 2017-12-31 | 2017-12-31 | One bacillus amyloliquefaciens and its application in preventing and treating autism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711496671.1A CN107828705A (en) | 2017-12-31 | 2017-12-31 | One bacillus amyloliquefaciens and its application in preventing and treating autism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107828705A true CN107828705A (en) | 2018-03-23 |
Family
ID=61645486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711496671.1A Pending CN107828705A (en) | 2017-12-31 | 2017-12-31 | One bacillus amyloliquefaciens and its application in preventing and treating autism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107828705A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109897795A (en) * | 2018-12-26 | 2019-06-18 | 佛山市艳晖生物科技有限公司 | A kind of microbial bacterial agent and its application on anti-treat constipation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102046784A (en) * | 2008-05-30 | 2011-05-04 | 帝斯曼知识产权资产管理有限公司 | Proline-specific protease from penicillium chrysogenum |
| CN102341009A (en) * | 2009-03-20 | 2012-02-01 | 诺维信公司 | Nutritional beverage and method of making same |
| EP2953474A2 (en) * | 2013-02-04 | 2015-12-16 | Seres Therapeutics, Inc. | Compositions and methods |
| CN106389479A (en) * | 2016-11-28 | 2017-02-15 | 青岛东海药业有限公司 | Application of bacillus coagulans in preparing preparation for preventing or treating autism |
-
2017
- 2017-12-31 CN CN201711496671.1A patent/CN107828705A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102046784A (en) * | 2008-05-30 | 2011-05-04 | 帝斯曼知识产权资产管理有限公司 | Proline-specific protease from penicillium chrysogenum |
| CN102341009A (en) * | 2009-03-20 | 2012-02-01 | 诺维信公司 | Nutritional beverage and method of making same |
| EP2953474A2 (en) * | 2013-02-04 | 2015-12-16 | Seres Therapeutics, Inc. | Compositions and methods |
| CN105451561A (en) * | 2013-02-04 | 2016-03-30 | 赛里斯治疗公司 | Compositions and methods |
| CN106389479A (en) * | 2016-11-28 | 2017-02-15 | 青岛东海药业有限公司 | Application of bacillus coagulans in preparing preparation for preventing or treating autism |
Non-Patent Citations (4)
| Title |
|---|
| SYDNEY M FINEGOLD: "Desulfovibrio species are potentially important in regressive autism", 《MED HYPOTHESES》 * |
| 张振等: "《益生菌在儿科临床中的应用》", 31 December 2011, 湖北科学技术出版社 * |
| 栾素军等: "解淀粉芽孢杆菌在畜禽养殖中的应用研究进展", 《中国畜牧兽医》 * |
| 段云峰等: "自闭症的病因和治疗方法研究进展", 《中国科学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109897795A (en) * | 2018-12-26 | 2019-06-18 | 佛山市艳晖生物科技有限公司 | A kind of microbial bacterial agent and its application on anti-treat constipation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112175864B (en) | Bifidobacterium animalis and breeding method and application thereof | |
| CN102827796B (en) | Lactobacillus plantarum with cadmium removing function and usage thereof | |
| JP2007518693A5 (en) | ||
| CN107619811A (en) | Lactobacillus plantarum CCFM200 bacterial strains and application | |
| CN104381440B (en) | Lactobacillus fermenti Lactobacillus fermentum strain Lee working stock cultures products and its Constipation health purpose | |
| CN109161509A (en) | One plant of bacterial strain that can prevent and treat cattle and sheep diarrhoeal diseases | |
| CN105039223A (en) | Bacillus subtilis with effect of inhibiting clostridium perfringens and application of bacillus subtilis | |
| CN106389479A (en) | Application of bacillus coagulans in preparing preparation for preventing or treating autism | |
| CN104430847A (en) | Lactobacillus fermentum Lee working leavening agent product and constipation-prevention and health application thereof | |
| CN110292585A (en) | For treating the intestinal flora capsule and preparation method that crystal methamphetamine habituation is given up | |
| CN103082294A (en) | Application of bacteroides fragilis in preparation of composition for treating diarrhea | |
| CN104435069B (en) | It is a kind of improve pig immune function animal medicinal composition, using and preparation method thereof | |
| CN114262677A (en) | Lactobacillus plantarum and application thereof in preventing and/or treating inflammatory bowel diseases | |
| CN109652334A (en) | A kind of complex microbial inoculum and its preparation method and application | |
| CN107828705A (en) | One bacillus amyloliquefaciens and its application in preventing and treating autism | |
| CN104845897A (en) | Bacillus subtilis, and breeding method and application thereof | |
| CN103266076B (en) | Space-induced efficient bifidobacterium bifidum and application thereof as well as preparation method of capsule preparation of space-induced efficient bifidobacterium bifidum | |
| CN104031856B (en) | Lactobacillus casei and application and functional food composition and preparation method thereof | |
| CN106387314A (en) | Applications of Bacteroides fragilis in animal breeding | |
| CN105343132B (en) | Composition, the drug and preparation method thereof for treating colitis | |
| US8748158B2 (en) | Microorganism having gastric-juice promoting activity, and its secretory product | |
| CN104651271A (en) | Lactobacillus casei strain Qian working leavening agent product and intestinal tract regulating health use thereof | |
| CN103266077B (en) | Space-induced efficient bifidobacterium longum, application thereof, and preparation method of capsule preparation thereof | |
| CN101450083A (en) | Use of clostridium butyricum in preparing composition for treating newborn feeding intolerance | |
| CN107586746A (en) | One plant of lactic acid bacteria with preventing and treating mastitis for milk cows effect and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180323 |